Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?

Myelodysplastic syndromes (MDS) are heterogeneous hematopoietic neoplasms that are driven by somatically acquired genetic mutations and epigenetic alterations. Accurate risk stratification is essential for delivery of risk-adaptive therapeutic interventions. The current prognostic tools sum the impa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Nazha, Aziz, Sekeres, Mikkael A., Gore, Steven D., Zeidan, Amer M.
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2015
Matèries:
Hematologic Malignancies
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4571815/
https://ncbi.nlm.nih.gov/pubmed/26194858
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0067
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars